文献速递肺结节与肺癌

Nazartinib(EGF816)在EGFR突变非小细胞肺癌成人患者中的安全性和疗效:一项多中心、开放标签、1期研究

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study.
PubMed 文献 · Lancet Respir Med · 2020-01-15

该1期剂量递增研究纳入180例晚期EGFR突变NSCLC患者,口服Nazartinib(75-350 mg每日一次),未达到最大耐受剂量,推荐2期剂量为150 mg每日一次(片剂)。最常见不良事件为皮疹(62%)、腹泻(45%)等,多为1-2级;任何原因的3-4级不良事件发生率为55%。结论认为Nazartinib安全性良好,皮肤毒性以斑丘疹为主且需减量的情况少。

要点

  • Nazartinib推荐2期剂量为150 mg每日一次(片剂),未达到最大耐受剂量。
  • 常见不良事件为皮疹(62%)、腹泻(45%)、瘙痒(39%)等,多为1-2级。
  • 任何原因3-4级不良事件发生率为55%,常见为皮疹(15%)、肺炎(7%)等。

核心结论

  • Nazartinib在晚期EGFR突变NSCLC患者中具有可接受的安全性,皮肤毒性以斑丘疹为主且需减量的情况少。

研究设计与样本

  • 多中心、开放标签、1/2期研究的1期剂量递增部分,在欧、亚、北美9个学术医疗中心开展。
  • 纳入180例≥18岁、IIIB-IV期EGFR突变NSCLC患者,ECOG评分≤2,至少一个可测量病灶。
  • Nazartinib口服每日一次,连续28天为一周期,剂量范围75-350 mg,共7个剂量水平。
  • 采用两参数贝叶斯逻辑回归模型(过量控制递增原则)推荐剂量并估计最大耐受剂量或推荐2期剂量(主要终点)。

主要发现

  • 180例患者中女性116例(64%),中位年龄60岁(52-69),ECOG评分1分者116例(64%)。
  • 7例剂量限制性毒性发生于6例(3%)接受150 mg、225 mg或350 mg每日一次的患者。
  • 最常见任何原因不良事件:皮疹(所有亚类111例[62%],斑丘疹72例[40%],痤疮样皮炎22例[12%])、腹泻81例(45%)、瘙痒70例(39%)、乏力54例(30%)、口腔炎54例(30%),多为1-2级。
  • 任何原因3-4级不良事件发生于99例(55%)患者,最常见为皮疹(所有亚类合计27例[15%])、肺炎12例(7%)、贫血10例(6%)、呼吸困难9例(5%)。
  • 疑似药物相关严重不良事件发生于16例(9%)患者。

关键数值与推荐

  • 推荐2期剂量为150 mg每日一次(片剂)。
  • 最大耐受剂量未达到。
  • 剂量限制性毒性共7例,发生于6例(3%)患者。

临床怎么用

  • Nazartinib 150 mg每日一次可作为EGFR突变NSCLC的推荐2期剂量。
  • 治疗期间需监测皮疹、腹泻等不良事件,多数为低级别且需减量的情况少。

局限性

  • 本文为1期剂量递增部分,样本量有限,疗效数据未在摘要中报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Resistance to first-generation and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is mediated by the emergence of the Thr790Met mutation in 50-60% of treated patients with non-small-cell lung cancer (NSCLC). We aimed to assess the safety and activity of nazartinib (EGF816), a third-generation EGFR TKI that selectively inhibits EGFR with Thr790Met or activating mutations (or both), while sparing wild-type EGFR, in patients with advanced EGFR-mutant NSCLC. METHODS: This phase 1 dose-escalation part of an open-label, multicentre, phase 1/2 study was conducted at nine academic medical centres located in Europe, Asia, and North America. Patients were included if they were aged 18 years or older and had stage IIIB-IV EGFR-mutant NSCLC (with varying statuses of EGFR mutation and previous therapy allowed), at least one measurable lesion, and an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less. Nazartinib (at seven dose levels between 75 mg and 350 mg, in capsule or tablet form) was administered orally, once daily, on a continuous 28-day dosing schedule. A two-parameter Bayesian logistic regression model, guided by the escalation with overdose control principle, was implemented to make dose recommendations and estimate the maximum tolerated dose or recommended phase 2 dose of nazartinib (the primary outcome). This study is registered with ClinicalTrials.gov (NCT02108964); enrolment to phase 1 is complete and the study is ongoing. FINDINGS: By Aug 31, 2017, 180 patients (116 [64%] women; median age 60 years (52-69); 116 [64%] with ECOG performance status 1) received nazartinib across seven dose levels: 75 mg (n=17), 100 mg (n=38), 150 mg (n=73), 200 mg (n=8), 225 mg (n=28), 300 mg (n=5), and 350 mg (n=11). Seven dose-limiting toxicities were observed in six (3%) patients who received 150 mg, 225 mg, or 350 mg nazartinib once daily. Although the maximum tolerated dose was not met, the recommended phase 2 dose was declared as 150 mg once daily (tablet). The most common adverse events, regardless of cause, were rash (all subcategories 111 [62%] patients, maculopapular rash 72 [40%], dermatitis acneiform 22 [12%]), diarrhoea (81 [45%]), pruritus (70 [39%]), fatigue (54 [30%]), and stomatitis (54 [30%]), and were mostly grades 1-2. Any-cause grade 3-4 adverse events were reported in 99 (55%) patients across all doses, the most common being rash (all subcategories grouped 27 [15%]), pneumonia (12 [7%]), anaemia (ten [6%]), and dyspnoea (nine [5%]). Serious adverse events suspected to be drug-related occurred in 16 (9%) patients. INTERPRETATION: Nazartinib has a favourable safety profile, with low-grade skin toxicity characterised by a predominantly maculopapular rash that required minimal dose reductions. FUNDING: Novartis Pharmaceuticals Corporation.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Tan DS, Leighl NB, Riely GJ, et al. Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. Lancet Respir Med. 2020. PMID: 31954624. doi:10.1016/S2213-2600(19)30267-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。